Lyell Immunopharma annual capital expenditures (capex)
2019
2020
2021
2022
2023
2024
2025
Lyell Immunopharma Capital Expenditures (CapEx) Growth & History (LYEL)
Lyell Immunopharma's capital expenditures (capex) was $780,000 for fiscal 2025.
View full Lyell Immunopharma company overviewLyell Immunopharma annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $780,000 | $316,000 | +68.10% |
| 2024 | 2024-12-31 | $464,000 | −$2.2M | −82.73% |
| 2023 | 2023-12-31 | $2.7M | −$21.6M | −88.94% |
| 2022 | 2022-12-31 | $24.3M | −$41.2M | −62.94% |
| 2021 | 2021-12-31 | $65.5M | $14.0M | +27.24% |
| 2020 | 2020-12-31 | $51.5M | $35.4M | +220.81% |
| 2019 | 2019-12-31 | $16.0M | — | — |
Lyell Immunopharma quarterly capital expenditures (capex)
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $256,000 | $88,000 | +52.38% |
| Q1 2026 | 2026-03-31 | $89,000 | −$157,000 | −63.82% |
| Q4 2025 | 2025-12-31 | $304,000 | $260,000 | +590.91% |
| Q3 2025 | 2025-09-30 | $62,000 | $3,000 | +5.08% |
| Q2 2025 | 2025-06-30 | $168,000 | −$163,000 | −49.24% |
| Q1 2025 | 2025-03-31 | $246,000 | $216,000 | +720.00% |
| Q4 2024 | 2024-12-31 | $44,000 | $19,000 | +76.00% |
| Q3 2024 | 2024-09-30 | $59,000 | −$136,000 | −69.74% |
| Q2 2024 | 2024-06-30 | $331,000 | −$602,000 | −64.52% |
| Q1 2024 | 2024-03-31 | $30,000 | −$1.5M | −98.04% |
| Q4 2023 | 2023-12-31 | $25,000 | −$4.6M | −99.45% |
| Q3 2023 | 2023-09-30 | $195,000 | −$2.6M | −93.01% |
| Q2 2023 | 2023-06-30 | $933,000 | −$6.2M | −86.99% |
| Q1 2023 | 2023-03-31 | $1.5M | −$8.2M | −84.25% |
| Q4 2022 | 2022-12-31 | $4.6M | −$5.7M | −55.38% |
| Q3 2022 | 2022-09-30 | $2.8M | −$8.8M | −75.94% |
| Q2 2022 | 2022-06-30 | $7.2M | −$17.3M | −70.67% |
| Q1 2022 | 2022-03-31 | $9.7M | −$9.5M | −49.28% |
| Q4 2021 | 2021-12-31 | $10.3M | — | — |
| Q3 2021 | 2021-09-30 | $11.6M | −$1.0M | −8.24% |
| Q2 2021 | 2021-06-30 | $24.4M | — | — |
| Q1 2021 | 2021-03-31 | $19.2M | — | — |
| Q3 2020 | 2020-09-30 | $12.6M | — | — |
Lyell Immunopharma capital expenditures (capex) trends
Over the last five fiscal years, Lyell Immunopharma's capital expenditures (capex) decreased from $51.5M to $780,000, a change of −$50.7M. The latest reported quarter, Q2 2026, shows $256,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lyell Immunopharma source filings ↗